Figure 1: A metabolic use-case comprehensive patient journey view with taXonomy Pathways In clinical trials, GLP-1 drugs showed high adherence (over 85% of patients stayed on therapy), yet real-world use tells a different story: one large study found only 32% of obese patients remained on a GLP-1 therapy after one year, with just 27% meeting standard adherence thresholds
The Precision Peptide Genetic Test identifies how your body processes GLP-1 and GIP signaling through analysis of key genetic variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313)
(Encinitas) 13 , 812 (2014)
Pour celles et ceux exposs des facteurs acclrant le vieillissement cellulaire : stress, pollution, tabac, fatigue chronique
as well as the hippocampus
With ongoing advances in oral formulations, combination therapies and expanded metabolic disease applications, the sector continues to attract significant scientific, clinical and investor attention while reshaping the future landscape of obesity and cardiometabolic treatment
